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Triple-	negative	breast	cancer	(TNBC)	is	an	aggressive	breast	cancer	subtype	with	
poor	survival	outcomes.	Currently,	there	are	no	targeted	therapies	available	for	
TNBCs	despite	remarkable	progress	 in	targeted	and	 immune-	directed	therapies	
for	 other	 solid	 organ	 malignancies.	 Poly	 (ADP-	ribose)	 polymerase	 inhibitors	
(PARPi)	are	effective	anticancer	drugs	that	produce	good	initial	clinical	responses,	
especially	in	homologous	recombination	DNA	repair-	deficient	cancers.	However,	
resistance	is	the	rule	rather	than	the	exception,	and	recurrent	tumors	tend	to	have	
an	aggressive	phenotype	associated	with	poor	survival.	Many	efforts	have	been	
made	to	overcome	PARPi	resistance,	mostly	by	targeting	genes	and	effector	pro-
teins	participating	 in	homologous	 recombination	 that	 are	overexpressed	during	
PARPi	therapy.	Due	to	many	known	and	unknown	compensatory	pathways,	genes,	
and	effector	proteins,	overlap	and	shared	resistance	are	common.	Overexpression	
of	programmed	cell	death-	ligand	1	(PD-	L1)	and	cancer	stem	cell	(CSC)	sparing	are	
novel	 PARPi	 resistance	 hypotheses.	 Although	 adding	 programmed	 cell	 death-	1	
(PD-	1)/PD-	L1	inhibitors	to	PARPi	might	improve	immunogenic	cell	death	and	be	
crucial	for	durable	responses,	they	are	less	likely	to	target	the	CSC	population	that	
drives	recurrent	tumor	growth.	Lysine-	specific	histone	demethylase-	1A	and	his-
tone	 deacetylase	 inhibitors	 have	 shown	 promising	 activity	 against	 CSCs.	
Combining	 epigenetic	 drugs	 such	 as	 lysine-	specific	 histone	 demethylase-	1A	 in-
hibitors	or	histone	deacetylase	inhibitors	with	PARPi/anti-	PD-	1/PD-	L1	is	a	novel,	
potentially	 synergistic	 strategy	 for	 priming	 tumors	 and	 overcoming	 resistance.	
Furthermore,	such	an	approach	could	pave	the	way	for	the	identification	of	new	
upstream	epigenetic	and	genetic	signatures.
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1  | BACKGROUND
Triple-	negative	 breast	 cancers	 (TNBCs)	 comprise	 approximately	
15%-	20%	of	breast	cancers	and	have	an	aggressive	natural	history	
compared	to	other	breast	cancer	subtypes.1	Triple-	negative	breast	
cancers	tend	to	present	in	younger,	premenopausal	women	and	pref-
erentially	metastasize	 to	visceral	organs.1	Despite	good	 responses	
to	 standard	cytotoxic	 chemotherapy	 regimens,	 recurrence	 is	 com-
mon,	and	retreatment	with	 further	 lines	of	chemotherapy	remains	
standard	 with	 suboptimal	 survival	 outcomes.	 Novel	 therapeutic	
drug	development	for	TNBCs	has	been	limited	due	to	their	heterog-
enous	nature.	There	is	thus	an	unmet	need	to	improve	therapeutic	
strategies	for	patients	with	TNBCs.	In	this	review,	we	explore	poly	
(ADP-	ribose)	 polymerase	 inhibitor	 (PARPi)	 resistance	mechanisms,	
hypothesize	novel	 resistance	pathways,	and	propose	a	novel	com-
binatorial	biological	approach	that	not	only	overcomes	PARPi	resis-
tance	but	also	renders	tumors	more	susceptible	to	immunogenic	cell	
death	 and	 depletes	 the	 metastasis-	driving	 cancer	 stem	 cell	 (CSC)	
population	through	epigenetic	modulation.
Immune	 checkpoint	 inhibition	 and	 immune-	mediated	 cytotox-
icity	 have	 shown	 impressive	 durable	 activity	 in	many	 hematologi-
cal	 and	 solid	 organ	 cancers	 with	 an	 acceptable	 toxicity	 profile.2 
Although	a	 large	proportion	of	TNBCs	express	high	 levels	of	pro-
grammed	cell	death-	ligand	1	 (PD-	L1),	have	a	high	mutational	 load,	
and	 are	 associated	 with	 high	 numbers	 of	 CD8+	 tumor-	infiltrating	
lymphocytes,	 responses	 to	 immunotherapy	 are	not	 as	 spectacular	
in	TNBCs	compared	to	other	cancers	(Table 1),3	but	numerous	trials	
including	multiple	combinations	are	ongoing.
Poly	 (ADP-	ribose)	polymerase	 inhibitors	are	group	of	relatively	
novel	drugs	 that	cause	cell	 cycle	arrest	and	cell	death	by	 interfer-
ing	with	DNA	 repair.4	 Several	PARPi	have	been	 tested	 in	patients	
with	various	cancers	including	ovarian,	breast,	and	prostate	cancers.	
Impressive	 responses	 have	mainly	 been	 seen	 in	 early	 phase	 trials	
and	some	phase	III	trials,	especially	in	BRCA-	mutant	ovarian	cancer	
patients	 (Table 2).	 Three	PARPi	 (olaparib,	 rucaparib,	 and	 niraparib)	
are	already	approved	by	the	US	FDA	for	the	treatment	of	recurrent	
ovarian	cancer	and,	recently,	olaparib	also	received	approval	for	the	
treatment	of	BRCA-	mutant	human	epidermal	growth	factor	receptor	
2-	negative	metastatic	breast	cancer.	Despite	promising	early	data,	
resistance	 develops	 in	most	 patients	with	 no	 significant	 improve-
ment	in	overall	survival	(OS).5,6
2  | POLY (ADP-  RIBOSE) POLYMER A SE 
AND PARPI
The	role	of	PARP1	in	DNA	damage	responses	is	diverse	and	has	been	
extensively	studied	(Figure	S1).	Poly	(ADP-	ribose)	polymerase	1	activ-
ity	 is	 triggered	by	binding	of	PARP1	to	single-	strand	breaks	 through	
the	 two	zinc	 fingers	 at	 the	N-	terminal	42	kDa	DNA-	binding	domain,	
which	leads	to	enzymatic	activation.7	Using	NAD	as	a	substrate,	PARP1	
catalyzes	 the	 transfer	of	 polymer	of	ADP	 ribose	 (PAR)	molecules	 to	
glutamate,	 lysine,	 or	 aspartate	 residues	 on	 acceptor	 histone	 and/or	
non-	histone	proteins,	thereby	mediating	the	recruitment	of	DNA	repair	
proteins	and	eventually	DNA	repair.	AutoPARylation	of	PARP1	eventu-
ally	enables	dissociation	of	PARP1	from	DNA	to	complete	DNA	repair.7
The	effects	of	PARPi	on	DNA	damage	and	the	cell	cycle	are	com-
plex.	Most	PARPi	are	competitive	NAD+	inhibitors	that	are	cytotoxic	
by	 inhibiting	 PARylation	 and	 by	 trapping	 PARP1	 on	 DNA,	 which	
blocks	the	progression	of	replication	forks,	eventually	leading	to	cell	
death.8	In	contrast,	a	recent	report	suggested	that	PARPi	might	in-
crease	the	speed	of	fork	elongation	(rather	than	stalling	it)	beyond	a	
tolerable	threshold,	eventually	leading	to	cell	death.9
Synthetic	 lethality	 is	 a	 concept	 in	 which	 defects	 in	 one	 or	 two	
genes/repair	mechanisms	have	minimal	effects	on	 the	cell,	whereas	
defects	 in	 combinations	 of	 genes/repair	 mechanisms	 are	 lethal.	
TABLE  1  Immunotherapy	in	breast	cancer
Citation Year Drug
Single agent/
combinations
Cancer subtype/
PD- L1 level Phase
No. of 
patients ORR% Comments
Loi	et	al68 2017 Pembrolizumab Trastuzumab ER+/−/PD-	L1+/− Ib/II 58 15 ORR	39%	in	
PD-	L1+,	TILs	
>5%
Rugo	et	al69 2016 Pembrolizumab Single	agent ER+HER2−/>1% Ib 25 12
Nanda	et	al70 2016 Pembrolizumab Single	agent TNBC/>1% Ib 27 18
Schmid	et	al71 2017 Atezolizumab Single	agent TNBC/>5% I 115 10 17%	ORR	in	
PD-	L1+
Adams	et	al72 2016 Atezolizumab Atezolizumab/
abraxane
TNBC,	PD-	L1+/− Ib 32 42
Dirix	et	al73 2016 Avelumab Single	agent HER2−/NR Ib 168 3 ORR;	TNBC	
22%,	
PD-	L1+	16%
Santa-	Maria	
et	al74
2017 Durvalumab Tremelimumab NR I 18 17 43%	in	TNBC
ER,	estrogen	receptor;	HER2,	human	epidermal	growth	factor	receptor	2;	NR,	not	reported;	ORR,	objective	response	rate;	PD-	L1,	programmed	cell	
death	ligand-	1;	TIL,	tumor	infiltrating	lymphocyte;	TNBC,	triple-	negative	breast	cancer.
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Farmer	et	al10	reported	that	homologous	recombination	(HR)-	deficient	
BRCA1/2-	mutated	 human	 cell	 lines	 and	 mouse	 models	 were	 much	
more	sensitive	to	PARPi	compared	to	BRCA	WT	cells.	Although	this	
synthetic	lethality	was	initially	thought	to	be	due	to	reliance	of	BRCA-	
mutant	 cells	on	 the	 single-	strand	break	 repair	 (base	excision	 repair)	
pathway	for	survival,	emerging	reports	suggests	that	PARP	trapping	
and	 subsequent	 generation	 of	 replication-	associated	 double-	strand	
breaks	(DSBs)	contribute	significantly	to	PARPi	lethality	in	the	context	
of	HR	deficiency.7	Clinically	used	PARPi	differ	in	their	cytotoxicity	and	
ability	to	“trap”	PARP1	on	DNA,	with	talazoparib	showing	higher	trap-
ping	potential	and	veliparib	limited	PARP	trapping	capacity.7
3  | POLY (ADP-  RIBOSE) POLYMER A SE 
INHIBITORS IN BRE A ST C ANCER
Triple-	negative	breast	cancers	comprise	15%-	20%	of	breast	cancers	
overall	 and	 70%	 of	 BRCA1	 and	 20%	 of	 BRCA2	 mutation	 carriers,	
respectively.11	 The	 initial	 discovery	of	 synthetic	 lethality	 in	BRCA-	
mutant	cancers	led	to	massive	interest	in	the	use	of	PARPi	in	patients	
with	breast	and	ovarian	cancers.	Response	rates	of	13%-	59%	were	
observed	in	multiple	phase	I	and	II	trials	(Table	 2),	with	even	higher	
responses	of	up	to	88%	observed	when	PARPi	were	combined	with	
chemotherapies.12	Subsequently,	two	large	phase	III	trials	reported	
the	efficacy	of	PARPi	in	BRCA-	mutant	metastatic	breast	cancers.	The	
OlympiAD	trial	compared	olaparib	300	mg	twice	daily	monotherapy	
to	physicians’	choice	chemotherapy	in	patients	with	germ-	line	BRCA-	
associated	breast	cancer.	The	olaparib	arm	showed	higher	response	
rates	 and	 longer	median	 progression-	free	 survival	 (PFS).	Although	
the	authors	reported	a	longer	second	PFS	benefit	with	olaparib,	this	
did	not	ultimately	translate	into	an	OS	advantage	(hazard	ratio,	0.90;	
P	=	.57);	however,	OS	was	not	the	predetermined	primary	end-	point	
of	the	study,	and	the	survival	analysis	might	have	been	affected	by	
subsequent	treatment	after	progression.5
The	 EMBRACA	 study	 had	 a	 similar	 patient	 cohort	 to	 that	 of	
OlympiAD	and	investigated	the	efficacy	of	talazoparib	in	metastatic	
BRCA-	mutant	breast	cancer	patients.	Among	431	patients,	the	PFS	
was	8.6	months	in	the	talazaparib	group	vs	5.6	months	in	the	control	
group.	Despite	 longer	 PFS	 and	 higher	 response	 rates,	 the	median	
duration	of	response	was	only	5.4	months	and	OS,	at	an	interim	anal-
ysis	after	51%	of	the	projected	events,	was	not	significantly	different	
between	groups	(hazard	ratio,	0.76;	P	=	.10).13	Despite	impressive	re-
sponses	and	PFS	benefit,	development	of	resistance	to	PARPi	was	
almost	ubiquitous,	hampering	the	duration	of	response	and	perhaps	
even	OS.	Furthermore,	PFS	benefit	was	in	the	range	of	2-	4	months	
with	 PARPi,	 even	 in	 germline	 BRCA-	mutant	 patients.	 Poly	 (ADP-	
ribose)	polymerase	inhibitors	have	been	investigated	extensively	in	
ovarian	cancers,	but	it	is	interesting	to	note	that,	despite	the	impres-
sive	PFS	benefits,	OS	differences	were	not	statistically	significant	in	
studies	that	have	reported	survival	data.14-16
4  | RESISTANCE TO PARPI
Poly	 (ADP-	ribose)	 polymerase	 inhibitor-	treated	 cells	 acquire	 resist-
ance	 either	 directly	 or	 indirectly	 related	 to	 restoration	of	HR	 repair	
or	through	other	mechanisms.	These	can	be	broadly	categorized	into	
7	 groups	 (Table 3);	 secondary	mutations	 that	 overcome	 the	 BRCA1	
pathway	deficiency	are	 the	best-	studied	mechanism	of	PARP	 resist-
ance.	Other	known	resistance	mechanisms	include	partial	or	complete	
restoration	of	HR	repair	through	rewiring	of	DNA	damage	response,	
either	through	 loss	of	53BP1	and	Shieldin	complex	proteins	that	re-
strain	DNA	end	resection,17	or	through	regulation	of	HR	genes.18	More	
recently,	SFLN11	has	emerged	as	a	promising	biomarker	of	PARPi	sen-
sitivity.	SFLN11	facilitates	DNA	replication	arrest	and	cell	death,	hence	
potentiating	the	“trapping”	effect	of	PARPi,19,20 and SLFN11	inactiva-
tion	confers	resistance	to	PARPi	in	many	cancer	cell	lines.21
5  | OVERCOMING RESISTANCE BY 
COMBINATION APPROACHES
Poly	(ADP-	ribose)	polymerase	inhibitor	combinations	tested	thus	far	
have	been	based	on	3	biological	interactions.
TABLE  2 Poly	(ADP-	ribose)	polymerase	inhibitor	trials	in	breast	cancer
Author Year Drug
Single agent/
combinations Phase No. of patients ORR% PFS (mo) OS (HR/P) OS (mo)
Litton	et	al13 2017 Talazoparib Single	agent	vs	
chemo
III 431 62 8.6	vs	5.6 (0.76/0.10) 22 vs 19
Robson  
et	al5
2017 Olaparib Single	agent	vs	
chemo
III 205 59	vs	28 7.0 vs 4.2 0.9	(0.57) 19.3 vs 
19.6
Kaufman	 
et	al75
2015 Olaparib Single	agent II 62 13 3.7 NA 11
Turner	et	al6 2017 Talazoparib Single	agent II 84 28 4 NA NR
Han	et	al76 2018 Veliparib V+Cb+P,	
Pl+Cb+P	(&	
V+Tem)
II 284 78	vs	61 14 vs 12 (0.75/0.1) 28	vs	26
Cb,	carboplatin;	chemo,	chemotherapy;	HR/P,	hazard	ratio/P	value;	NA,	not	applicable;	NR,	not	reported;	ORR,	overall	response	rate;	OS,	overall	sur-
vival;	P,	paclitaxel;	PFS,	progression-	free	survival;	Pl,	placebo;	Tem,	temozolomide;	V,	veliparib.
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5.1 | Increasing DNA damage
Poly	(ADP-	ribose)	polymerase	inhibitors	have	been	shown	to	increase	
the	DNA	damage	caused	by	cytotoxic	chemotherapy	or	by	interrupt-
ing	DNA	repair	pathways.	This	approach	was	limited	by	toxicity,	pre-
dominantly	myelosuppression,	despite	various	dose	and	scheduling	
modifications.12,22	 In	 addition,	many	DNA	 repair	 pathways	 are	 up-
regulated	to	compensate	for	PARPi	 (eg	CHK1/2,	CDK1,	Wee1,	and	
MET1),	and	interfering	with	these	can	augment	PARPi	efficacy.22
5.2 | Increasing PARP trapping
Poly	(ADP-	ribose)	polymerase	inhibitors	differ	in	their	ability	to	trap	
PARP1	 on	 DNA.	 Cytotoxicity	 was	 greater	 with	 olaparib/temozo-
lomide	 than	 veliparib/temozolomide,	 which	 was	 attributed	 to	 the	
greater	trapping	ability	of	olaparib	compared	to	veliparib.	However,	
synergy	between	topoisomerase	1	 inhibitors	and	PARPi	was	more	
dependent	on	catalytic	activity	 rather	 than	trapping.22	Hence,	ap-
propriate	selection	of	combinations	based	on	PARPi	biology	 is	 im-
portant	to	achieve	synergy.
5.3 | Simulating BRCAness in  
BRCA- proficient tumors
Some	tumors	inherently	express	BRCAness	despite	being	BRCA	pro-
ficient	and	could	be	sensitive	to	PARPi.	In	others,	silencing	BRCA	ex-
pression	or	depleting	proteins	involved	in	BRCA-	associated	HR	creates	
BRCAness	and	increases	PARPi	sensitivity.23	McCabe	et	al24	reported	
that	defects	 in	other	DNA	repair	genes	commonly	 found	 in	human	
cancers	 including	 those	 involved	 in	 DSB	 detection	 and	 repair	 ren-
dered	tumors	susceptible	to	PARPi.	Recently,	inhibition	of	BET	genes	
(in	particular	BRD4)	or	related	proteins	has	been	shown	to	sensitize	
cancers	to	PARPi	by	inducing	BRCAness	through	downregulation	of	
CTIP,	BRCA1,	 and	RAD51	 transcription.25,26	Deficiencies	 in	 several	
other	pathways	could	also	 increase	PARPi	 sensitivity,	 and	drugs	 in-
hibiting	the	mTOR/PI3K	pathway,	heat	shock	protein	90	(HSP90),	and	
histone	deacetylase	inhibitors	(HDACi)	are	currently	undergoing	trials.
6  | NOVEL THEORIES OF PARPI 
RESISTANCE
6.1 | Programmed cell death- ligand 1 theory
Cancer	 cells	 can	 be	 recognized	 and	 eliminated	 by	 the	 innate	 and	
adaptive	 immune	 systems,	 especially	 in	 the	 early	 course	of	 tumor	
development.	 T	 cell	 recognition	 of	 cancer	 antigens	 and	 activation	
are	crucial	 to	 immunogenic	cancer	cell	death,	which	 is	 initiated	by	
antigen	 presentation	 by	 antigen-	presenting	 cells.	 Tumor	 antigens	
are	 presented	 through	 the	MHC	 to	T-	cell	 receptors,	 facilitated	by	
co-	stimulatory	molecules	like	B7	and	CD28	to	fully	activate	T	cells.	
Various	 other	 co-	stimulatory	 and	 co-	inhibitory	 checkpoint	 mol-
ecules	have	been	 identified	 in	the	 last	decade	that	are	 involved	 in	
augmenting	or	suppressing	T	cell	activation.	Cancer	cells	develop	a	
variety	of	mechanisms	to	evade	immunogenic	cell	death	such	as	PD-	
L1	expression,	which	can	cause	T	cell	 suppression	when	bound	to	
programmed	cell	death-	1	(PD-	1)	(Figure 1).27
The	 combination	 of	 PARPi	 and	 immunotherapy	 is	 one	 novel	 ap-
proach	currently	being	investigated	(Table	S1).28,29	Several	arguments	
have	 been	 proposed	 to	 rationalize	 such	 combinations.	 First,	 PARPi-	
related	cytotoxicity	could	release	damaged	DNA,	which	represents	a	
source	of	potential	neoantigens	 that	make	 the	 tumor	more	 immuno-
genic.	Many	immunotherapeutic	agents	rely	on	neoantigens	expressed	
by	cancers	that	are	recognized	as	non-	self	by	T	cells.	Such	cancers	with	
high	mutational	and	neoantigen	load	are	very	vulnerable	to	checkpoint	
inhibition,	hence	the	excellent	responses	seen	in	selected	cancers	like	
melanoma,	 non-small	 cell	 lung	 cancer,	 renal	 cell	 carcinoma,	 and	mis-
match	repair-	deficient	colorectal	cancers.30	Second,	a	recent	study	by	
Jiao	et	al31	proposed	that	PARPi	could	induce	PD-	L1	expression.	In	this	
study,	treatment	of	MDA-	MB-	231	and	BT549	breast	cancer	cells	(basal	
breast	cancer	lines)	with	either	olaparib	or	talazoparib	increased	PD-	L1	
expression	in	vitro	and	in	vivo.	Inactivation	of	glycogen	synthase	kinase	
3α/β	by	PARPi	was	noted	to	be	a	key	step	in	the	upregulation	of	PD-	L1.	
Furthermore,	although	PARPi	were	associated	with	T	cell	 infiltration,	
the	proportion	of	infiltrating	cytotoxic	CD8+	cells	was	very	low,	thought	
to	be	due	to	 increased	PD-	L1.	Addition	of	PD-	L1	 inhibitors	to	PARPi	
reversed	PARP	resistance	and	increased	cytotoxic	CD8+	cells	(Figure 2).
Taking	all	this	evidence	together,	a	PARPi/PD-	1	inhibitor	(PD1i)	
combination	is	likely	to	show	synergy.	Nonetheless,	Higuchi	et	al32 
found	 that,	 although	 combined	 CTLA4	 and	 PARP1	 inhibition	was	
synergistic,	combining	a	PD-	L1/PD1i	with	a	PARP1i	had	no	effect.	
However,	 these	studies	have	notable	differences:	 the	former	used	
only	breast	cancer	cell	 lines	including	MDA-	MB-	231,	SUM149,	and	
TABLE  3 Poly	(ADP-	ribose)	polymerase	(PARP)	inhibitor	
resistance	in	breast	cancer
Mode of resistance Molecular mechanism
Restoration	of	BRCA1/2 Secondary	mutations77
Restoration	of	HR	repair Increased	RAD5178
HOXa9	depletion79
S6	ribosomal	
phosphorylation80
Loss	of	53BP1/Shieldin17
Reduced	access	to	drug Upregulation	of	the	Abcb1a/b 
gene	and	p-	GP	efflux	pump81
Enrichment/increase	in	resistant	
cells
CSC	enrichment40
Activation	of	EZH2	and	
increased	CSCs39
Increased	PARP	activity Activated	c-	Met	
proto-	oncogene82
Increased	PARP	levels83
Impaired	replication	arrest Downregulation	of	SLFN1119,21
Other Upregulation	of	NF-	κB	
signaling84
CSC,	cancer	stem	cell;	EZH2,	enhancer	of	zeste	homolog	2;	HOXa9,	ho-
meobox	 A9;	 HR,	 homologous	 recombinant;	 NF-	κB,	 nuclear	 factor-	κB;	
SLFN11,	Schlafen	family	member	11.
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F IGURE  1 Effect	of	poly	(ADP-	ribose)	polymerase	inhibitors	(PARPi)	in	the	tumor	microenvironment.	A,	Although	PARPi	might	cause	
initial	tumor	shrinkage,	they	could	promote	epithelial-	mesenchymal	transition	(EMT)	with	minimal	cytotoxicity	against	cancer	stem	cells	
(CSCs),	leading	to	CSC	enrichment.	Poly	(ADP-	ribose)	polymerase	inhibitors	might	also	upregulate	checkpoint	protein	expression,	such	
as	programmed	cell	death	ligand-	1	(PD-	L1).	B,	T	cells	are	inhibited	by	tumor-	T	cell	interactions	by	overexpressed	checkpoint	proteins,	for	
example,	PD-	L1-	programmed	cell	death-	1	interactions.	C,	Accelerated	epithelial-	mesenchymal	transition	and	enrichment	of	CSCs	with	
impaired	immunogenic	cell	death	leads	to	cancer	progression	and	metastasis	
F IGURE  2 Combination	strategy,	specifically	targeting	vital	resistance	pathways	that	are	likely	to	enhance	the	cytotoxicity	of	poly	
(ADP-	ribose)	polymerase	inhibitors	(PARPi).	Poly	(ADP-	ribose)	polymerase	inhibitor	therapy	increases	DNA	damage,	releases	tumor	antigens	
(neoantigens),	and	might	also	upregulate	checkpoint	proteins	like	programmed	cell	death	ligand-	1	(PD-	L1).	These	PARPi-	induced	changes	
are	likely	to	prime	tumors	and	render	them	sensitive	to	enhanced	immunogenic	cell	death.	However,	PARPi	and	checkpoint	inhibitors	are	
unlikely	to	have	any	effect	on	epithelial-	mesenchymal	transition	(EMT)	or	cancer	stem	cells	(CSCs).	Many	epigenetic	drugs,	especially	lysine-	
specific	demethylase-	1	inhibitors,	have	shown	promising	activity	in	inhibiting	CSCs	and	suppressing	EMT.	Furthermore,	reprogramming	
of	vital	immune-	and	homologous	recombination-	related	genes	through	specific	epigenetic	modulation	might	synergistically	enhance	the	
antitumor	activity	of	a	PARPi/checkpoint	inhibitor	combination	and	could	identify	novel	targetable	gene	signatures.	FoxP3+	Tregs,	Forkhead	
box	P3+	regulatory	T	cells;	MDSC,	myeloid-	derived	suppressor	cells;	PD-	1,	programmed	cell	death-	1;	TILs,	tumor-	infiltrating	lymphocytes
3388  |     PRASANNA et Al.
SUM159	with	olaparib	and	talazoparib	as	the	PARP1i,	whereas	the	
latter	 used	 the	 BR5-	Akt/BRCA1	 deficient	 and	 T22/BRCA1	 profi-
cient	ovarian	cancer	cell	lines	and	veliparib.
6.2 | Cancer stem cell theory
Cancer	stem	cells	are	a	small	subpopulation	of	cancer	cells	found	in	
the	tumor	mass	that	express	unique	cell	surface	marker	profiles	like	
CD44high/CD24low,	and	epithelial	cell	adhesion	molecule	(EPCAM)	in	
breast	cancer,	and	CD133	in	colon,	brain,	and	lung	cancers.33 There 
is	increasing	evidence	that	they	play	crucial	roles	in	tumorigenesis,	
invasion,	 and	metastasis.33	 Cancer	 stem	 cells	 are	 inherently	more	
resistant	to	standard	chemotherapy	and	radiotherapy,	so	are	impli-
cated	in	the	development	of	tumor	progression,	resistance,	metas-
tasis.34	Many	features	of	CSCs	confer	the	drug-	resistant	phenotype:	
reduced	proliferation	rate/quiescence,	adaptation	to	hostile	condi-
tions	 such	as	 inflammation	and	 low	nutrient	availability,	metabolic	
reprogramming,	 marked	 resistance	 to	 oxidative	 stress,	 the	 ability	
to	 rapidly	 activate	 detoxifying	 strategies	 by	 ATP-	binding	 cassette	
transporters,	enhanced	and	quick	DNA	damage	responses,	and	im-
paired	apoptotic	machinery.35
6.2.1 | Epithelial- mesenchymal transition 
(EMT) and CSCs
Epithelial-	mesenchymal	 transition	 is	 a	 latent	 embryonic	 program	
implicated	 in	 cancer	 invasion	 and	 metastasis.36	 In	 EMT,	 epithelial	
cancer	cells	lose	their	adhesive	properties	and	acquire	a	mesenchy-
mal	 trait.	 Epithelial-	mesenchymal	 transition	 is	 a	 complex	 process	
that	 involves	many	 transcription	 factors	 including,	 but	 not	 limited	
to,	 SNAIL,	 SLUG,	 TWIST,	 ZEB1,	 SIP1,	 and	 E47.	 Many	 pathways	
play	 crucial	 roles	 in	 EMT	 such	 as	Wnt,	 Notch,	 nuclear	 factor-	κB,	
Hedgehog,	and	transforming	growth	factor-	β	(TGF-	β).37	Cells	under-
going	 EMT	 can	 acquire	 stem	 cell-	like	 features	 to	 become	CSCs.38 
The	 tumor	 microenvironment	 also	 plays	 a	 crucial	 role	 in	 exerting	
selective	pressure	during	the	development	of	CSCs	with	metastatic	
properties,	a	process	attributed	to	multiple	cytokines	participating	
in	the	various	pathways	mentioned	above	and	derived	from	the	sur-
rounding	stroma	and	stromal	cells	including	tumor-	associated	mac-
rophages	and	cancer-	associated	fibroblasts.35
6.2.2 | Effect of PARPi on CSCs
The	 role	of	PARPi	on	CSCs	 is	unknown;	however,	 there	 is	 indirect	
evidence	to	suggest	CSCs	are	resistant	to	PARPi.	Yamaguchi	et	al39 
reported	that	inhibition	of	PARP1	with	olaparib	activated	EZH2	and	
increased	 the	 formation	 of	 breast	 cancer	 CSCs.	 In	 another	 study	
of	 human	TNBC	cell	 lines,	 even	 though	 tumor	bulk	 reduced	when	
treated	with	a	PARPi,	there	was	CSC	sparing.40	Various	other	features	
of	CSCs	are	described	that	confer	resistance	to	standard	therapeu-
tics	(Table 4).	Poly	(ADP-	ribose)	polymerase	inhibitors	share	many	of	
these	mechanisms,	and	 it	 is	 reasonable	 to	presume	that	PARPi	are	
very	unlikely	to	exert	significant	cytotoxicity	on	CSCs	(Figure 1).
6.2.3 | Effect of PD- 1/PD- L1 inhibitors on CSCs
The	direct	impact	of	immunotherapy	on	the	CSC	population	is	cur-
rently	unknown;	however,	it	is	unlikely	to	have	a	significant	impact	
on	its	own	based	on	current	evidence.
Hugo	et	al41	examined	the	genomic	and	transcriptomic	features	
of	 responders	 and	non-	responders	 in	 pretreatment	 tumor	 speci-
mens	 of	metastatic	melanomas	 from	patients	 treated	with	PD1i.	
Resistant	signatures	in	nonresponders	included	genes	involved	in	
angiogenesis,	 immunosuppression,	 monocyte/macrophage	 che-
motaxis,	and	EMT.	Gene	ontology	enrichment	and	gene	set	variant	
analysis	also	confirmed	that	these	tumor	specimens	were	enriched	
in	 EMT	 and	TGF-	β	 pathway	 genes,	 both	 of	which	 are	 implicated	
in	CSC	development.	In	addition,	Wu	et	al42	reported	high	PD-	L1	
levels	in	breast	and	colon	CSCs	compared	to	non-	CSCs.	Expression	
profiling	 of	 large	 breast	 cancer	 datasets	 revealed	 a	 positive	
Target Mechanism
Canonical	pathways Inhibitors	of	Src	and	FAK	tyrosine	kinases
Inhibitors	of	PI3K/Atk/mTOR
STAT3	inhibitors
Signaling	cascades	in	EMT 1.	Stemness	signaling	pathway
•	 	EGFR	TKIs	like	icotinib,	which	can	convert	CSCs	
to	non-CSCs
•	 Inhibiting	Wnt/β-catenin	or	Notchb.
2.	EMT	signaling	pathway
•	 Hedgehog,	TGF-β
Surface	markers CD133,	CD44,	ESA,	ALDH1
Manipulation	of	miRNA	expression miR-	21,	miR-	24
Epigenetic	manipulation See	text
ALDH1,	 aldehyde	 dehydrogenase	 1;	 EGFR,	 epidermal	 growth	 factor	 receptor;	 EMT,	 epithelial-	
mesenchymal	transition;	miR,	microRNA;	TGF-	β,	transforming	growth	factor-	β;	TKI,	tyrosine	kinase	
inhibitor.
TABLE  4 Potential	pathways	and	
therapeutic	strategies	against	cancer	stem	
cells	(CSCs)
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correlation	between	the	stemness	score	of	the	breast	cancer	and	
PD-	L1	 levels.43	 Furthermore,	 PD-	L1	 knockdown	 decreased	 ex-
pression	of	embryonic	stem	cell	transcription	factors	like	octamer-	
binding	 transcription	 factor-	4A,	Nanog,	 and	 the	 stemness	 factor	
BMI1.	Wnt	signaling	might	also	be	associated	with	PD1i	resistance,	
and	Wnt	is	a	crucial	pathway	in	EMT	and	CSC	formation.44
7  | EPIGENETIC S
Epigenetics	 is	 defined	 as	 heritable	 modifications	 to	 DNA	 without	
alteration	in	the	nucleotide	sequence,	resulting	in	altered	gene	tran-
scription	and	chromatin	structure.45	Epigenetic	changes	include	DNA	
methylation	 and	 post-	translational	 histone	 modifications	 involving	
methylation	or	acetylation.	A	hallmark	of	epigenetic	changes	is	their	
reversibility,	which	contrasts	with	the	irreversible	nature	of	the	gene	
sequence.	Aberrations	in	DNA	methylation	and	histone	methylation	
and	acetylation,	often	involving	tumor	promotors	or	suppressors,	are	
associated	with	tumorigenesis	so	are	potential	drug	targets.45
7.1 | Lysine- specific histone demethylase- 1A 
(LSD1) and LSD1 inhibitors
Lysine-	specific	 histone	 demethylase-	1A	 specifically	 demethylates	
mono-	or	dimethylated	histone3	lysine4	(H3K4)	or	histone3	lysine9	
(H3K9).	Lysine-	specific	histone	demethylase-	1A	is	required	for	normal	
stem	cell	differentiation	and	maintenance.	It	is	overexpressed	in	some	
cancers	including	bladder,	prostate,	and	lung	cancers.46 LSD1	knock-
down	 reduces	LSD1	expression	and	 inhibits	 cancer	 growth,	migra-
tion,	and	invasion.	In	breast	cancer,	LSD1	expression	increases	when	
ductal	carcinoma	in	situ	progresses	to	invasive	ductal	carcinoma.47 In 
addition,	LSD1	is	overexpressed	in	TNBCs,	and	their	stemness	prop-
erties	proportionately	 increase	with	LSD1	expression.48	High	LSD1	
levels	 are	 seen	during	EMT	 in	MCF-	7	breast	 cancer	 cells	 following	
stimulation	with	Phorbol	12-	myristate-	13-	acetate/TGF-	β	and	in	fully	
dedifferentiated	 mesenchymal	 MDA-	MB-	231	 breast	 cancer	 cells.	
Decreased	LSD1	levels	have	also	been	reported	during	the	opposing	
biological	process,	mesenchymal-	epithelial	transition.49
Boulding	et	al49	showed	that	treatment	of	 induced	MCF-	7	cells	
with	LSD1	siRNA	completely	abolished	the	CD44+/CD24−	CSC	pop-
ulation,	and	pharmacological	inhibition	with	a	known	LSD1	inhibitor	
pargyline	partially	inhibited	CSC	formation.	In	addition,	LSD1	inhibi-
tion	reduced	EMT	and	stemness-	like	resistance	signatures	induced	
by	chemotherapy.49	 In	vivo	inhibition	of	LSD1	in	combination	with	
chemotherapy	 reduced	 tumor	 growth	 compared	 to	 chemotherapy	
alone.	Given	these	findings,	LSD1	inhibitors	have	the	potential	to	act	
as	anticancer	agents	in	breast	cancer	due	to	the	pathway’s	clear	role	
in	EMT	and	CSC	formation.
7.2 | Histone deacetylase and HDACi
Histone	 deacetylase	 is	 a	 family	 of	 hydrolases	 that	 remove	 acetyl	
groups	 from	 lysine	 residues	 on	 histones,	 and	 they	 play	 important	
and	varied	roles	in	tumorigenesis,	including	regulation	of	numerous	
genes	 responsible	 for	 tumor	 initiation	 and	 progression,	 angiogen-
esis,	 and	 cell	migration.50	 Therefore,	HDACi	 have	 emerged	 as	 po-
tential	anticancer	drugs	that	inhibit	DNA	repair.	In	addition,	HDACi	
seem	to	be	cytotoxic	 to	breast	cancer	CSCs.	Hsieh	et	al51 showed 
that	HDAC3	was	linked	to	CSC	homeostasis	by	increasing	β-	catenin	
expression	through	the	Akt/glycogen	synthase	kinase	3β	pathway.	
Other	preclinical	models	also	have	shown	the	impact	of	HDACi	on	
CSCs.51,52
However,	 single-	agent	 epigenetic	 drugs	 have	 failed	 to	 show	
clinical	activity	in	many	solid	organ	malignancies	despite	impressive	
activity	in	multiple	cell	lines	in	preclinical	models,	perhaps	because	
they	are	not	DNA	damaging	on	their	own	and	due	to	the	develop-
ment	of	resistance.53	Hence,	there	is	growing	evidence	and	interest	
in	 their	use	 in	combination	with	other	anticancer	drugs,	especially	
with	PARPi	and	immunotherapies.
7.3 | Do epigenetic drugs synergize with PARPi and 
PD1i?
7.3.1 | Epigenetic drugs and PARPi
Epigenetic	 drugs	 might	 synergize	 with	 PARPi	 in	 several	 ways.	 As	
discussed	above,	PARPi	exert	their	cytotoxicity	by	increasing	DNA	
damage	and	generating	lesions	that	require	HR,	hence	the	synthetic	
lethality	seen	with	defective	HR.	Epigenetic	drugs	might	affect	the	
DNA	repair	pathways	directly	or	indirectly.	Histone	deacetylase	in-
hibition	downregulates	genes	involved	in	DNA	damage	response	and	
repair	pathways.	Prostate	cancer	cells	inhibited	with	HDACi	showed	
increased	sensitivity	to	DNA-	damaging	agents,54	an	effect	thought	
to	 be	 related	 to	 downregulation	 of	 the	 transcription	 factor	 E2F1.	
Further	 supporting	 this,	 PCI-	24781,	 an	HDACi,	 decreased	 RAD51	
and	HR	pathway	expression.55	In	this	background,	many	epigenetic	
drugs	 have	 been	 combined	with	 PARPi	 in	 the	 hope	 of	 enhancing	
DNA	damage	and	inducing	BRCAness.56
Muvarak	et	al57	described	a	different	mode	of	interaction,	noting	
that	low-	dose	DNA	methyltransferase	inhibitor	(DNMTi)	combined	
with	talazoparib	enhanced	tight	binding	of	talazoparib	to	DNA	and	
increased	DSB	 formation	 and	 cytotoxicity	 in	MDA-	MB-	231	TNBC	
stem	cell-	like	cell	 lines.	Bhalla	et	al58	reported	that	HDACi	blocked	
the	deacetylation	of	HSP90,	which	led	to	hyperacetylation	and	in-
hibition	of	HSP90	and	many	of	its	chaperone	proteins	RAD52,	Atr,	
and	checkpoint	kinase	1,	all	of	which	are	involved	in	HR	and	again	
potentially	inducing	BRCAness.
Epigenetic	drugs	might	also	improve	the	clinical	efficacy	of	PARPi	
through	their	 impact	on	CSCs.	In	addition	to	the	effect	of	LSD1i	on	
CSCs,	other	studies	have	shown	the	effect	of	DNMTi	and	HDACi	on	
CSCs.	Azacytidine,	a	DNMTi,	reduced	the	CD44+/CD24−/ALDH+	pop-
ulation	in	T47D	breast	cancer	cells.	Furthermore,	there	was	downreg-
ulation	of	key	EMT	regulatory	pathway	genes	like	TWIST,	SLUG,	and	
SNAIL.59	Liu	et	al40	 reported	 that	PARPi	with	olaparib	caused	a	1.9-	
fold	 increase	 in	CSCs	 in	BRCA-	mutant	SUM149	and	HCC-	1937	cells	
without	changes	in	absolute	CSC	numbers.	Addition	of	vorinostat,	a	
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pan-	HDAC	inhibitor,	reduced	the	absolute	number	of	CSCs	in	SUM149,	
SUM159,	 and	HCC1397	 cultures	 and	 sensitized	 the	 TNBC	CSCs	 to	
PARPi	 irrespective	of	 the	BRCA	 status.	 The	 researchers	 also	 found	
reduced	 formation	of	RAD51	foci	at	 sites	of	DNA	damage	with	 the	
addition	of	vorinostat,	hence	creating	a	BRCAness	phenotype.40
7.3.2 | Epigenetics and immunotherapy
Epigenetic	drugs	 could	potentiate	 the	 antitumor	 activity	of	 immuno-
therapy	by	either	reducing	F	Forkhead	box	P3+	regulatory	T	cells,	re-
ducing	 circulating	 and	 tumor-	infiltrating	 myeloid-	derived	 suppressor	
cells,	or	by	upregulating	PD-	L1	and/or	PD-	L2	expression,	thereby	 in-
creasing	T	cell	infiltration	of	tumors	and	augmenting	antigen	presenta-
tion	by	MHC.60-63	The	immune-	priming	effect	of	epigenetic	drugs	was	
observed	in	a	clinical	trial	setting	in	2011,	when	6	patients	were	treated	
with	dual	epigenetic	therapy	(azacytidine	and	entinostat)	but	failed	to	
show	any	clinical	responses.	Subsequently,	these	patients	were	enrolled	
into	an	 immunotherapy	trial	and	showed	remarkable	 responses,	with	
5	of	 them	experiencing	a	PFS	of	over	6	months	and	2	 living	for	over	
4 years.64	However,	it	should	be	noted	that	not	all	the	results	in	this	field	
are	consistent.	A	number	of	clinical	trials	are	now	prospectively	inves-
tigating	the	utility	of	combined	epigenetic	drugs	and	immunotherapy.
8  | FINAL DISCUSSION AND FUTURE 
STR ATEGIES
The	combination	of	PARPi	with	a	PD-	1	or	PD-	L1	inhibitor	has	a	very	
promising	 biological	 rationale	 for	 synergy;	 however,	 as	 discussed	
above,	both	drugs	are	unlikely	to	have	a	significant	impact	on	CSCs.	
This	 could	 lead	 to	 residual	 tumors	 enriched	with	CSCs	 that	might	
eventually	 relapse,	 progress,	 and	metastasize	despite	 initial	 tumor	
shrinkage.	Hence,	it	is	of	the	utmost	importance	that	future	thera-
peutic	strategies	should	incorporate	drugs	targeting	CSCs.
Many	therapeutic	approaches	are	being	investigated	for	targeting	
CSCs,	with	potential	targets	including	signaling	cascades	or	transcrip-
tion	 factors	 involved	 in	EMT.	 It	 is	apparent	 that	 there	 is	 significant	
crosstalk	between	multiple	signaling	cascades	and	transcription	fac-
tors,	so	combination	therapies	are	likely	to	be	needed.	Occasionally,	
such	crosstalk	may	be	beneficial,	as	inhibition	of	one	factor	might	also	
result	in	downregulation	of	the	other;	however,	such	close	interaction	
could	also	lead	to	upregulation	of	an	alternative	pathway,	as	seen	with	
PARPi.	 Kwon	 et	al65	 reported	 an	 interaction	 between	 membrane-	
associated	Notch	and	β-	catenin,	showing	that	inhibition	of	the	Notch	
pathway	(with	PF-	03084014)	 inhibited	the	Wnt	pathway	as	well	as	
decreasing	β-	catenin	levels	post-	translationally.	However,	prolonged	
inhibition	of	Notch	has	also	been	shown	to	cause	compensatory	ac-
tivation	of	Hedgehog	signaling	in	the	skin.66	Hedgehog	signaling	was	
found	to	inhibit	Wnt	signaling	through	upregulation	of	secreted	friz-
zled-related	protein	1,	so	inhibition	of	the	Hedgehog	pathway	could	
potentially	activate	Wnt	signaling.67
We,	 therefore,	 believe	 that	 combination	 strategies	 targeting	
multiple	 signals	 in	 the	 same	 cascade	 are	 less	 likely	 to	 provide	 an	
acceptable	 clinical	 yield,	 especially	with	 respect	 to	 long-	term	 sur-
vival,	due	to	the	numerous	genes,	signaling	pathways,	and	effector	
proteins	involved.	The	effect	of	epigenetic	drugs	on	CSCs	is	an	up-
stream	effect	that	is	likely	to	have	controlled	inhibition/regulation	of	
all	corresponding	downstream	cascades.
Although	toxicity	is	always	a	concern	with	combination	therapy,	
as	seen	in	PARPi/chemotherapy	trials,	 it	 is	possible	that	 low	doses	
of	epigenetic	drugs	could	be	adequate	to	induce	durable	responses,	
hence	the	risk	of	added	toxicity	is	expected	to	be	lower	when	used	
in	this	way.59	In	addition,	the	rate	of	serious	toxicity	is	low	with	PD1i	
and	the	spectrum	of	toxicity	is	distinct	to	the	other	two	drug	classes.
We	propose	the	addition	of	epigenetic	drugs	to	a	PARPi/PD1i	com-
bination	might	be	synergistic	and	could	potentially	overcome	different	
resistance	mechanisms,	causing	cytotoxic	cell	death	by	DNA	damage,	
suppression	of	CSCs,	and	potentiating	immunogenic	cell	death	(Figure 2).	
Furthermore,	such	novel	combination	strategies	could	uncover	new	epi-
genetic	 or	 gene	 signatures	 related	 to	DNA	 repair,	 PD-	L1	 expression,	
and/or	CSC	formation,	which	could	be	potential	targets	for	future	ther-
apies.	Correction	of	such	upstream	targets	or	aberrations	might	avoid	
the	need	to	use	multiple	drugs	to	target	multiple	downstream	signals.
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